Breadth of expertise in business, philanthropy, community engagement, and venture capital to help advance Foundation’s mission
Site Search
Groups urging need for revitalizing antimicrobial development call for passage of the bill this year
Brown to join Foundation in April 2023, bringing more than 20 years of experience in nonprofit communications and journalism, with a focus on health and science
Human resources veteran Massenburg brings more than 20 years of leadership experience in nonprofit and business sectors
Update: On February 3, 2017, the Cystic Fibrosis Foundation divested its remaining ownership stake in CF Services Inc., a specialty pharmacy. The pharmacy is now fully owned by Walgreens.
Potential oral formulation of drug targeting nontuberculous mycobacteria infections could reduce side effects of current treatment
Nonprofit issues challenge to accelerate treatments for every person with CF
Update: On February 3, 2017, the Cystic Fibrosis Foundation divested its remaining ownership stake in CF Services Inc., a specialty pharmacy. The pharmacy is now fully owned by Walgreens.
Today, the Cystic Fibrosis Foundation announced that it awarded funding to enGene Inc. to develop a customized vehicle to deliver genetic-based therapies, such as gene therapy and gene editing, into the lung cells of people with cystic fibrosis (CF). Delivering genetic-based therapies to the lungs is a key hurdle to developing effective treatments for all people with CF, including individuals with two nonsense and rare mutations.